Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial (Q81230426)
Jump to navigation
Jump to search
scientific article published on 19 September 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial |
scientific article published on 19 September 2005 |
Statements
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial (English)
Brian Weinshenker
Hillel Panitch
Douglas Goodin
Gordon Francis
Peter Chang
Patricia Coyle
Paul O'Connor
David Li
EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group
19 September 2005